59 results on '"Soentjens, Patrick"'
Search Results
2. Schistosomiasis in the Military-A Narrative Review.
- Author
-
Costescu Strachinaru DI, Nyandwaro JN, Stoefs A, Dooms E, Vanbrabant P, François PM, Strachinaru M, Van Esbroeck M, Bottieau E, and Soentjens P
- Abstract
Schistosomiasis is a parasitosis caused by trematodes of the genus Schistosoma . Humans are infected when coming into contact with freshwater containing the parasites' infective stages, which are amplified through freshwater-dwelling snails acting as intermediate hosts. Schistosomiasis has posed significant problems for troops exposed to freshwater in endemic regions ever since the Napoleonic wars. Schistosomiasis has substantial differences in clinical presentation, depending on the type of parasite, intensity of infection and reinfection, clinical form, and disease stage. It can remain undiagnosed for long periods of time, with well-known long-term morbidity and mortality risks. The diagnosis of schistosomiasis depends on its stage and relays on several tests, all with limitations in sensitivity and specificity. The diagnostic gold standard is the detection of eggs in urine, feces, or tissue biopsies, but this can raise problems in patients such as military personnel, in which the worm burden is usually low. Praziquantel is the drug of choice for schistosomiasis. Currently, there is no available commercial vaccine against any Schistosoma parasite. Avoiding freshwater exposure is the best prevention. Herein, we review the clinical presentation, diagnosis, treatment, and prevention of schistosomiasis in the military. This information may decrease the impact of schistosomiasis on this particular professional group.
- Published
- 2024
- Full Text
- View/download PDF
3. Rabies post-exposure prophylaxis: A retrospective analysis of timing of initiation and antibody responses in a Belgian cohort.
- Author
-
Hens M, Declercq S, Berens-Riha N, Maniewski U, Theunissen C, Van Den Broucke S, De Bièvre F, Brosius I, Liesenborghs L, Van Dijck C, Burm C, Nauwelaers I, Balliauw K, Visser BJ, Bottieau E, and Soentjens P
- Abstract
Background: We aimed to determine the timeliness of rabies post-exposure prophylaxis (PEP) and the proportion of individuals with an adequate antibody response post-PEP among those attending the Belgian national reference center., Methods: Retrospective analysis of patient records who attended our center from 2018 to 2023. Delay was defined as rabies immunoglobulin (RIG) and vaccine initiation beyond 2 calendar days after exposure. Antibodies were measured by rapid fluorescent focus inhibition test (RFFIT) after PEP in high-risk exposures. A titer ≥0.5 IU/ml was considered adequate., Results: We reviewed 317 patient records. Among individuals with inland exposure (n = 103), 85 % timely received PEP. Among travelers exposed abroad (n = 214), administration of RIG and vaccine initiation were timely in 30 % and 50 % of cases, respectively. An adequate antibody response was detected in 99.5 % (195/196) individuals., Conclusion: Substantial PEP delays among travelers were observed. The robust antibody responses suggest that routine serological follow-up is not necessary for all patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Streamlining malaria prevention recommendations for travellers: current and future approaches.
- Author
-
McGuinness SL, Veit O, Angelin M, Antonini P, Boecken G, Boering M, Bühler S, Calleri G, Éperon G, Flaherty G, Gossner C, Askling HH, Holmberg V, Kuenzli E, Landry P, Lefevre E, Libman M, Longley N, Maniewski-Kelner U, Neumayr A, Rapp C, Ridpath AD, Rodriguez N, Rosdahl A, Rosenbusch D, Rossanese A, Rothe C, Schlagenhauf P, Soentjens P, Staehelin C, Visser J, Visser L, Wagner A, Walker A, Wiedermann U, Wroczynska A, and Hatz C
- Published
- 2024
- Full Text
- View/download PDF
5. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
- Author
-
Steenackers K, Hanning N, Bruckers L, Desombere I, Marchant A, Ariën KK, Georges D, Soentjens P, D'Onofrio V, Hites M, Berens-Riha N, De Coster I, and Damme PV
- Subjects
- Humans, Adult, Male, Female, Middle Aged, 2019-nCoV Vaccine mRNA-1273 immunology, Young Adult, ChAdOx1 nCoV-19 immunology, Single-Blind Method, Immunogenicity, Vaccine, Healthy Volunteers, Vaccination methods, Antibodies, Viral blood, Antibodies, Viral immunology, SARS-CoV-2 immunology, COVID-19 prevention & control, COVID-19 immunology, Immunity, Humoral, Immunization Schedule, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, BNT162 Vaccine immunology, BNT162 Vaccine administration & dosage, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Immunoglobulin G blood, Immunization, Secondary
- Abstract
Background: To overcome supply issues of COVID-19 vaccines, this partially single blind, multi-centric, vaccine trial aimed to evaluate humoral immunogenicity using lower vaccine doses, intradermal vaccination, and heterologous vaccine schedules. Also, the immunity after a booster vaccination was assessed., Methodology: 566 COVID-19-naïve healthy adults were randomized to 1 of 8 treatment arms consisting of combinations of BNT162b2, mRNA-1273, and ChAdOx1-S. Anti-Receptor-Binding Domain immunoglobulin G (RBD IgG) titers, neutralizing antibody titres, and avidity of the anti-RBD IgGs was assessed up to 1 year after study start., Results: Prolonging the interval between vaccinations from 28 to 84 days and the use of a heterologous BNT162b2 + mRNA-1273 vaccination schedule led to a non-inferior immune response, compared to the reference schedule. A low dose of mRNA-1273 was sufficient to induce non-inferior immunity. Non-inferiority could not be demonstrated for intradermal vaccination. For all adapted vaccination schedules, anti-RBD IgG titres measured after a first booster vaccination were non-inferior to their reference schedule., Conclusion: This study suggests that reference vaccine schedules can be adapted without jeopardizing the development of an adequate immune response. Immunity after a booster vaccination did not depend on the dose or brand of the booster vaccine, which is relevant for future booster campaigns. The trial is registered in the European Union Clinical Trials Register (number 2021-001993-52) and on clinicaltrials.gov (NCT06189040)., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Pierre Van Damme reports financial support was provided by Belgian Health Care Knowledge Centre. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper]., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.
- Author
-
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B, Soentjens P, Lavigne R, and Merabishvili M
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Adult, Treatment Outcome, Aged, Precision Medicine methods, Adolescent, Young Adult, Bacteria virology, Bacteria genetics, Child, Aged, 80 and over, Child, Preschool, Belgium, Infant, Phage Therapy methods, Bacteriophages physiology, Bacteriophages genetics, Anti-Bacterial Agents therapeutic use, Bacterial Infections therapy
- Abstract
In contrast to the many reports of successful real-world cases of personalized bacteriophage therapy (BT), randomized controlled trials of non-personalized bacteriophage products have not produced the expected results. Here we present the outcomes of a retrospective observational analysis of the first 100 consecutive cases of personalized BT of difficult-to-treat infections facilitated by a Belgian consortium in 35 hospitals, 29 cities and 12 countries during the period from 1 January 2008 to 30 April 2022. We assessed how often personalized BT produced a positive clinical outcome (general efficacy) and performed a regression analysis to identify functional relationships. The most common indications were lower respiratory tract, skin and soft tissue, and bone infections, and involved combinations of 26 bacteriophages and 6 defined bacteriophage cocktails, individually selected and sometimes pre-adapted to target the causative bacterial pathogens. Clinical improvement and eradication of the targeted bacteria were reported for 77.2% and 61.3% of infections, respectively. In our dataset of 100 cases, eradication was 70% less probable when no concomitant antibiotics were used (odds ratio = 0.3; 95% confidence interval = 0.127-0.749). In vivo selection of bacteriophage resistance and in vitro bacteriophage-antibiotic synergy were documented in 43.8% (7/16 patients) and 90% (9/10) of evaluated patients, respectively. We observed a combination of antibiotic re-sensitization and reduced virulence in bacteriophage-resistant bacterial isolates that emerged during BT. Bacteriophage immune neutralization was observed in 38.5% (5/13) of screened patients. Fifteen adverse events were reported, including seven non-serious adverse drug reactions suspected to be linked to BT. While our analysis is limited by the uncontrolled nature of these data, it indicates that BT can be effective in combination with antibiotics and can inform the design of future controlled clinical trials. BT100 study, ClinicalTrials.gov registration: NCT05498363 ., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. COVID-19 in three waves in a tertiary referral hospital in Belgium: a comparison of patient characteristics, management, and outcome.
- Author
-
De Paepe A, Vlieghe E, Brusselaers N, Soentjens P, Theunissen C, Brosius I, Grouwels J, Van Petersen L, van Tiggelen H, Verbrugghe W, Jorens PG, Lapperre T, Peeters K, Vermeulen G, and van Ierssel SH
- Subjects
- Humans, Belgium epidemiology, Male, Female, Retrospective Studies, Middle Aged, Aged, Hospitalization statistics & numerical data, Risk Factors, Aged, 80 and over, Adult, Treatment Outcome, Severity of Illness Index, Comorbidity, Intensive Care Units statistics & numerical data, COVID-19 epidemiology, COVID-19 therapy, COVID-19 mortality, Tertiary Care Centers statistics & numerical data, SARS-CoV-2
- Abstract
Purpose: Few studies have compared patient characteristics, clinical management, and outcome of patients with COVID-19 between the different epidemic waves. In this study, we describe patient characteristics, treatment, and outcome of patients admitted for COVID-19 in the Antwerp University Hospital over the first three epidemic waves of 2020-2021., Methods: Retrospective observational study of COVID-19 patients in a Belgian tertiary referral hospital. All adult patients with COVID-19, hospitalized between February 29, 2020, and June 30, 2021, were included. Standardized routine medical data was collected from patient records. Risk factors were assessed with multivariable logistic regression., Results: We included 722 patients, during the first (n = 179), second (n = 347) and third (n = 194) wave. We observed the lowest disease severity at admission during the first wave, and more elderly and comorbid patients during the second wave. Throughout the subsequent waves we observed an increasing use of corticosteroids and high-flow oxygen therapy. In spite of increasing number of complications throughout the subsequent waves, mortality decreased each wave (16.6%,15.6% 11.9% in 1st, 2nd and 3rd wave respectively). C-reactive protein above 150 mg/L was predictive for the need for intensive care unit admission (odds ratio (OR) 3.77, 95% confidence interval (CI) 2.32-6.15). A Charlson comorbidity index ≥ 5 (OR 5.68, 95% CI 2.54-12.70) and interhospital transfers (OR 3.78, 95% CI 2.05-6.98) were associated with a higher mortality., Conclusions: We observed a reduction in mortality each wave, despite increasing comorbidity. Evolutions in patient management such as high-flow oxygen therapy on regular wards and corticosteroid use may explain this favorable evolution., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort study.
- Author
-
Brosius I, Van Dijck C, Coppens J, Vandenhove L, Bangwen E, Vanroye F, Verschueren J, Zange S, Bugert J, Michiels J, Bottieau E, Soentjens P, van Griensven J, Kenyon C, Ariën KK, Van Esbroeck M, Vercauteren K, and Liesenborghs L
- Subjects
- Humans, Longitudinal Studies, Prospective Studies, Virus Shedding, Ambulatory Care Facilities, Mpox (monkeypox)
- Abstract
The risk of infection after exposure to clade IIb mpox virus (MPXV) is unknown, and potential presymptomatic shedding of MPXV remains to be demonstrated. High-risk contacts of mpox patients were followed-up in a prospective longitudinal cohort study. Individuals reporting sexual contact, >15 min skin-to-skin contact, or living in the same household with an mpox patient were recruited in a sexual health clinic in Antwerp, Belgium. Participants kept a symptom diary, performed daily self-sampling (anorectal, genital, and saliva), and presented for weekly clinic visits for physical examination and sampling (blood and oropharyngeal). Samples were tested for MPXV by PCR. Between June 24 and July 31, 2022, 25 contacts were included, of which 12/18 (66.0%) sexual and 1/7 (14.0%) nonsexual contacts showed evidence of infection by MPXV-PCR. Six cases had typical mpox symptoms. Viral DNA was detected as early as 4 days before symptom onset in 5 of them. In 3 of these cases, replication-competent virus was demonstrated in the presymptomatic phase. These findings confirm the existence of presymptomatic shedding of replication-competent MPXV and emphasize the high risk of transmission during sexual contact. Sexual contacts of mpox cases should abstain from sex during the incubation period, irrespective of symptoms., (© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
9. Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-Centre, randomized controlled pilot trial.
- Author
-
Berens-Riha N, Andries P, Aerssens A, Ledure Q, Vanderbeken Y, Heyndrickx L, Genbrugge E, Tsoumanis A, Van Herrewege Y, Ariën KK, Van Innis M, Vanbrabant P, and Soentjens P
- Abstract
Background: The purpose of this exploratory study was to evaluate different accelerated tick-borne encephalitis (TBE) vaccine schedules for last-minute travellers., Methods: In a single-centre, open-label pilot study, 77 TBE-naïve Belgian soldiers were randomized to one of the following five schedules with FSME-Immun®: group 1 ('classical accelerated' schedule) received one intramuscular (IM) dose at day 0 and day 14, group 2 two IM doses at day 0, group 3 two intradermal (ID) doses at day 0, group 4 two ID doses at day 0 and day 7, group 5 two ID doses at day 0 and day 14. The last dose(s) of the primary vaccination scheme were given after one year: IM (1 dose) or ID (2 doses). TBE virus neutralizing antibodies were measured in a plaque reduction neutralization test (PRNT90 and 50) at day 0, 14, 21, 28, month 3, 6, 12, and 12 + 21 days. Seropositivity was defined as neutralizing antibody titres ≥10., Results: The median age was 19-19.5 years in each group. Median time-to-seropositivity up to day 28 was shortest for PRNT90 in ID-group 4 and for PRNT50 in all ID groups. Seroconversion until day 28 peaked highest for PRNT90 in ID-group 4 (79%) and for PRNT50 in ID-groups 4 and 5 (both 100%). Seropositivity after the last vaccination after 12 months was high in all groups. Previous yellow fever vaccination was reported in 16% and associated with lower GMTs of TBE-specific antibodies at all time points. The vaccine was generally well tolerated. However, mild to moderate local reactions occurred in 73-100% of ID compared to 0-38% of IM vaccinations, persistent discolouration was observed in nine ID vaccinated individuals., Conclusion: The accelerated two-visit ID schedules might offer a better immunological alternative to the recommended classical accelerated IM schedule but an aluminium-free vaccine would preferable., (© The Author(s) 2023. Published by Oxford University Press on behalf of International Society of Travel Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
10. Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak.
- Author
-
Hens M, Brosius I, Berens-Riha N, Coppens J, Van Gestel L, Rutgers J, Kenyon C, Soentjens P, van Henten S, Bracke S, Vanbaelen T, Vandenhoven L, Bottieau E, Vercauteren K, Van Esbroeck M, Liesenborghs L, and Van Dijck C
- Abstract
Background: The presentation of mpox clade IIb during the 2022 outbreak overlaps with a range of other diseases. Understanding the factors associated with mpox is important for clinical decision making., Methods: We described the characteristics of mpox patients who sought care at Belgian sexual health clinic. Furthermore we compared their characteristics to those of patients with a clinical suspicion of mpox but who tested negative on polymerase chain reaction., Results: Between May 23 and September 20, 2022, 155 patients were diagnosed with mpox, and 51 patients with suspected symptoms tested negative. All mpox patients self-identified as men and 148/155 (95.5%) as gay or bisexual MSM. Systemic symptoms were present in 116/155 (74.8%) patients. All but 10 patients (145/155, 93.5%) presented with skin lesions. Other manifestations were lymphadenopathy (72/155, 46.5%), proctitis (50/155, 32.3%), urethritis (12/155, 7.7%), tonsillitis (2/155, 1.3%). Complications involved bacterial skin infection (13/155, 8.4%) and penile oedema with or without paraphimosis (4/155, 2.6%). In multivariable logistic regression models, the presence of lymphadenopathy (OR 3.79 95% CI 1.44-11.49), skin lesions (OR 4.35 95% CI 1.15-17.57) and proctitis (OR 9.41 95% CI 2.72-47.07) were associated with the diagnosis of mpox. There were no associations with age, HIV status, childhood smallpox vaccination, number of sexual partners and international travel., Conclusions: The presence of proctitis, lymphadenopathies and skin lesions should increase clinical suspicion of mpox in patients with compatible symptoms., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
11. Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022.
- Author
-
Berens-Riha N, Bracke S, Rutgers J, Burm C, Van Gestel L, Hens M, Kenyon C, Bottieau E, Soentjens P, Brosius I, Van Esbroeck M, Vercauteren K, van Griensven J, van Dijck C, and Liesenborghs L
- Subjects
- Humans, Belgium epidemiology, Follow-Up Studies, Morbidity, Prospective Studies, Disease Outbreaks, Mpox (monkeypox) epidemiology, Mpox (monkeypox) pathology
- Abstract
While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3-20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers.
- Published
- 2023
- Full Text
- View/download PDF
12. Alternative sampling specimens for the molecular detection of mpox (formerly monkeypox) virus.
- Author
-
Coppens J, Vanroye F, Brosius I, Liesenborghs L, van Henten S, Vanbaelen T, Bracke S, Berens-Riha N, De Baetselier I, Kenyon C, Soentjens P, Florence E, Van Griensven J, Ariën KK, Jacobs BKM, Van den Bossche D, Van Esbroeck M, and Vercauteren K
- Subjects
- Humans, Edetic Acid, Polymerase Chain Reaction, Nucleic Acid Amplification Techniques, Monkeypox virus genetics, Mpox (monkeypox) diagnosis
- Abstract
Background: Mpox (formerly monkeypox) is a viral disease caused by the mpox virus (MPXV), endemic in Central and West Africa and currently causing a global outbreak of international concern. Much remains unknown about sample types most suited for mpox laboratory diagnosis. While it is established that high viral loads can be found in active skin lesions (currently the recommended mpox laboratory confirmation specimen type), WHO mpox testing guidelines encourage the use of oropharyngeal swabs as an additional sample type for mpox diagnosis and suggest investigating the value of other specimens like blood samples., Objective: In this study, we verified the value of select alternative specimen types for mpox laboratory confirmation., Methods: We included 25 patients with MPXV-confirmed skin lesions to compare diagnostic sensitivity of MPXV PCR testing on EDTA plasma and two upper respiratory specimens: oropharyngeal swabs and saliva., Results: In our patient cohort with MPXV-confirmed skin lesions, diagnostic sensitivity of MPXV PCR was 80% in EDTA plasma, 64% in oropharyngeal swabs, and 88% in saliva. MPXV viral loads were significantly higher in saliva compared to oropharyngeal swabs and EDTA plasma., Discussion: The WHO recommendation to collect oropharyngeal swabs as an additional specimen for mpox diagnosis might need to be revised to include saliva wherever feasible. We suggest investigating saliva as a diagnostic specimen in the absence of active skin lesions or during the phase preceding skin manifestations. Moreover, the relatively high MPXV DNA content of saliva warrants elucidating its potential role in disease transmission., Competing Interests: Declaration of Competing Interest None, (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022.
- Author
-
Berens-Riha N, De Block T, Rutgers J, Michiels J, Van Gestel L, Hens M, Kenyon C, Bottieau E, Soentjens P, van Griensven J, Brosius I, Ariën KK, Van Esbroeck M, Rezende AM, Vercauteren K, and Liesenborghs L
- Subjects
- Humans, Belgium epidemiology, Vaccination adverse effects, Mpox (monkeypox) prevention & control, Smallpox Vaccine adverse effects
- Abstract
Vaccination is important in containing the 2022 mpox (formerly monkeypox) epidemic. We describe five Belgian patients with localised severe symptoms of proctitis and penile oedema, occurring between 4 and 35 days after post-exposure preventive vaccination or after one- or two-dose off-label pre-exposure preventive vaccination with MVA-BN vaccine. Genome sequencing did not reveal evidence for immune escape variants. Healthcare workers and those at risk should be aware of possible infections occurring shortly after vaccination and the need for other preventive measures.
- Published
- 2022
- Full Text
- View/download PDF
14. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler.
- Author
-
Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, Schroven K, Paeshuyse J, de Magnée C, Sokal E, Stéphenne X, Scheers I, Rodriguez-Villalobos H, Djebara S, Merabishvili M, Soentjens P, and Pirnay JP
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Child, Preschool, Humans, Male, Bacteriophages, Liver Transplantation, Phage Therapy, Pseudomonas Infections therapy
- Abstract
Post-operative bacterial infections are a leading cause of mortality and morbidity after ongoing liver transplantation. Bacteria causing these infections in the hospital setting can exhibit high degrees of resistance to multiple types of antibiotics, which leads to major therapeutic hurdles. Alternate ways of treating these antibiotic-resistant infections are thus urgently needed. Phage therapy is one of them and consists in using selected bacteriophage viruses - viruses who specifically prey on bacteria, naturally found in various environmental samples - as bactericidal agents in replacement or in combination with antibiotics. The use of phage therapy raises various research questions to further characterize what determines therapeutic success or failure. In this work, we report the story of a toddler who suffered from extensively drug-resistant Pseudomonas aeruginosa sepsis after liver transplantation. He was treated by a bacteriophage-antibiotic intravenous combination therapy for 86 days. This salvage therapy was well tolerated, without antibody-mediated phage neutralization. It was associated with objective clinical and microbiological improvement, eventually allowing for liver retransplantation and complete resolution of all infections. Clear in vitro phage-antibiotic synergies were observed. The occurrence of bacterial phage resistance did not result in therapeutic failure, possibly due to phage-induced virulence tradeoffs, which we investigated in different experimental models., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
15. Incidence and predictors of severe altitude illness symptoms in Mt. Kilimanjaro hikers: a prospective cohort study.
- Author
-
Croughs M, Nyakunga GB, Sakita FM, Kilonzo K, Mmbaga BT, and Soentjens P
- Subjects
- Acute Disease, Altitude, Humans, Incidence, Prospective Studies, Tanzania epidemiology, Altitude Sickness epidemiology, Altitude Sickness prevention & control, Mountaineering
- Abstract
Background: Each year several Mt. Kilimanjaro hikers die due to altitude illness (AI) although urgent descent is technically easily possible. The objectives of this study were to determine the incidence and predictors of severe altitude illness (SAI) symptoms and of summit success in Mt. Kilimanjaro hikers, and the measures taken when AI symptoms develop., Methods: A prospective observational cohort study in Mt. Kilimanjaro hikers was conducted from December 2019 until March 2020. Participants were asked to complete a questionnaire at the entrance gate and one at the descend gate. A multivariate logistic regression was performed to study the relations between the variables., Results: A total of 1237 recreational hikers and 266 porters or guides were included. The incidence of severe symptoms was 8.6% in recreational hikers and 1.5% in porters and guides. One percent (1.1%) of hikers was hospitalized due to SAI. A history of SAI, young age, summit failure and lack of clear advice predicted the development of severe symptoms. Uhuru peak was reached by 87.9% of the hikers. Absence of severe symptoms, acetazolamide prophylaxis, climbing higher in daytime, young age and climbing in more days predicted summit success. The majority climbed further despite the presence of mild or severe symptoms. The only measure taken in case of mild symptoms that was associated with a lower incidence of severe symptoms was not climbing further., Conclusion: The incidence of SAI symptoms in Mt. Kilimanjaro hikers was observed to be high. However, how hikers reacted during symptoms was not appropriate. Therefore, travel health counsellors should emphasize even more that hikers do not ascend higher until mild symptoms have resolved and that it is vital to descend immediately when severe symptoms develop. In addition, they can be informed on the measures, which improved summit success., (© The Author(s) 2022. Published by Oxford University Press on behalf of International Society of Travel Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
16. Human Filariasis in Travelers and Migrants: A Retrospective 25-year Analysis at the Institute of Tropical Medicine, Antwerp, Belgium.
- Author
-
Bottieau E, Huits R, Van Den Broucke S, Maniewski U, Declercq S, Brosius I, Theunissen C, Feyens AM, Van Esbroeck M, van Griensven J, Clerinx J, and Soentjens P
- Subjects
- Adult, Animals, Belgium epidemiology, Female, Humans, Male, Retrospective Studies, Elephantiasis, Filarial epidemiology, Loiasis diagnosis, Loiasis drug therapy, Loiasis epidemiology, Mansonelliasis diagnosis, Mansonelliasis drug therapy, Mansonelliasis epidemiology, Transients and Migrants, Tropical Medicine
- Abstract
Background: Information on human filariasis in international travelers is scarce. We describe the epidemiology, clinical presentation, and outcome of these infections in a reference travel clinic over the past decades., Methods: We reviewed all cases of filariasis diagnosed at the Institute of Tropical Medicine, Antwerp, Belgium, from 1994 to 2018. Diagnosis was obtained by either parasitological methods (confirmed) or strict clinical case definitions (probable). We assessed the characteristics of cases at diagnosis and response to therapy within 3-12 months., Results: A total of 320 patients (median age: 41 years; 71% males) were diagnosed with 327 filarial infections (Wuchereria bancrofti = 6, Onchocerca volvulus = 33, Loa loa = 150, Mansonella perstans = 130, unspecified species = 8). Diagnosis was confirmed in 213/320 (67%) patients. European long-term travelers accounted for 166 patients (52%) and visitors/migrants from tropical countries for another 110 (34%). Central Africa was the likely region of acquisition for 294 (92%) patients. The number of filariasis cases decreased from 21.5/year on average in the 1990s to 6.3/year in the past decade, when loiasis became predominant. Cases reported symptoms in >80% of all filarial infections but mansonellosis (45/123 single infections; 37%). Lymphatic filariasis and onchocerciasis cases responded well to conventional therapy. However, 30% of patients with loiasis and mansonellosis experienced treatment failure (with diethylcarbamazine and levamisole-mebendazole, respectively)., Conclusions: The burden and species distribution of filariasis in travelers evolved in the past decades. Most presentations were symptomatic. Case management would benefit from more effective therapies for loiasis and mansonellosis., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
17. A case of Flavonifractor plautii blood stream infection in a severe burn patient and a review of the literature.
- Author
-
Costescu Strachinaru DI, Gallez JL, Daras S, Paridaens MS, Engel H, François PM, Rose T, Vanbrabant P, and Soentjens P
- Subjects
- Clostridiales, Humans, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods, Bacteremia diagnosis, Bacteremia microbiology, Burns complications, Sepsis diagnosis, Sepsis microbiology
- Abstract
Background: Flavonifractor plautii is a strictly anaerobic rod shaped bacterium belonging to the family of Clostridiales . It is a commensal of the human intestinal microbiota which was seldom isolated from clinical samples, therefore clinical data are scarce. To date, only four cases of F. plautii infections were described, all occurring in immunosuppressed patients., Case Presentation: We report a case where F. plautii was isolated from the blood culture of a severe burn victim and identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry., Discussion: To the best of our knowledge, this is the first case of F. plautii blood stream infection described in a burn patient.
- Published
- 2022
- Full Text
- View/download PDF
18. Epidemiology and etiology of blood stream infections in a Belgian burn wound center.
- Author
-
Costescu Strachinaru DI, Gallez JL, François PM, Baekelandt D, Paridaens MS, Pirnay JP, De Vos D, Djebara S, Vanbrabant P, Strachinaru M, and Soentjens P
- Subjects
- Anti-Bacterial Agents therapeutic use, Belgium epidemiology, Humans, Microbial Sensitivity Tests, Retrospective Studies, Burn Units, Burns complications, Burns drug therapy, Burns epidemiology
- Abstract
Background: Infections are a major cause of morbidity in burn patients. We aimed to investigate the epidemiology and antibiotic susceptibility of blood stream infections in order to gain a better understanding of their role and burden in our Burn Wound Center., Methods: This retrospective epidemiological investigation analyzed data derived from medical files of patients admitted to our Burn Wound Center having had at least one positive blood culture between 1 January and 31 December 2018. We focused on the prevalence of causative agents in blood stream infections in function of the time after injury and on their drug sensitivity., Results: Among the 363 patients admitted to our Burn Wound Center during the study period, 29 had at least one episode of blood stream infection. Gram-negative organisms accounted for 56,36% of the pathogens in blood stream infections, Gram-positives for 38,17%, and yeasts for 5,45%. Pseudomonas aeruginosa was the most common bacterium (20%), followed by Staphylococcus epidermidis (16.36%), Escherichia coli and Klebsiella pneumoniae (9,09% each). A third of the Gram-negative isolates were multidrug resistant. Gram-positive cocci were isolated from blood cultures at a median of 9 days after the injury, earlier than Gram-negative rods (median 15 days). The main sources of blood stream infections were the burn wounds, followed by infected catheters., Conclusions: Multidrug resistant bacteria must be considered when selecting empirical antibiotic therapy in septic burn patients. In our center, we need to update our antibiotic guidelines, to review the hospital infection control measures and to introduce routine typing technology.
- Published
- 2022
- Full Text
- View/download PDF
19. A case of Escherichia coli and Peptoniphilus species mixed osteomyelitis successfully identified by MALDI TOF-MS with a review of the literature.
- Author
-
Costescu Strachinaru DI, Gallez JL, Paridaens MS, Djebara S, Soete O, and Soentjens P
- Subjects
- Female, Humans, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Escherichia coli, Osteomyelitis
- Abstract
Background: Peptoniphilus species are Gram-positive anaerobic cocci that are commensals of the human vagina and gut., Methods and Results: We describe a case of mixed Escherichia coli and Peptoniphilus spp. osteomyelitis identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry as Peptoniphilus harei and present a short literature review., Conclusion: To our knowledge, only six cases of P. harei osteomyelitis have been reported to date.
- Published
- 2022
- Full Text
- View/download PDF
20. Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load.
- Author
-
Mestdagh P, Gillard M, Dhillon SK, Pirnay JP, Poels J, Hellemans J, Hutse V, Vermeiren C, Boutier M, De Wever V, Soentjens P, Djebara S, Malonne H, André E, Arbyn M, Smeraglia J, and Vandesompele J
- Subjects
- Adult, COVID-19 etiology, Carrier State virology, Humans, Nasopharynx virology, Prospective Studies, Specimen Handling instrumentation, Viral Load, COVID-19 virology, COVID-19 Nucleic Acid Testing methods, Saliva virology, Specimen Handling methods
- Abstract
Nasopharyngeal swabs are considered the preferential collection method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Less invasive and simpler alternative sampling procedures, such as saliva collection, are desirable. We compared saliva specimens and nasopharyngeal (NP) swabs with respect to sensitivity in detecting SARS-CoV-2. A nasopharyngeal and two saliva specimens (collected by spitting or oral swabbing) were obtained from >2500 individuals. All samples were tested by RT-qPCR, detecting RNA of SARS-CoV-2. The test sensitivity was compared on the two saliva collections with the nasopharyngeal specimen for all subjects and stratified by symptom status and viral load. Of the 2850 patients for whom all three samples were available, 105 were positive on NP swab, whereas 32 and 23 were also positive on saliva spitting and saliva swabbing samples, respectively. The sensitivity of the RT-qPCR to detect SARS-CoV-2 among NP-positive patients was 30.5% (95% CI, 1.9%-40.2%) for saliva spitting and 21.9% (95% CI, 14.4%-31.0%) for saliva swabbing. However, when focusing on subjects with medium to high viral load, sensitivity on saliva increased substantially: 93.9% (95% CI, 79.8%-99.3%) and 76.9% (95% CI, 56.4%-91.0%) for spitting and swabbing, respectively, regardless of symptomatic status. Our results suggest that saliva cannot readily replace nasopharyngeal sampling for SARS-CoV-2 diagnostics but may enable identification of the most contagious cases with medium to high viral loads., (Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations.
- Author
-
Pirnay JP, Selhorst P, Hong SL, Cochez C, Potter B, Maes P, Petrillo M, Dudas G, Claes V, Van der Beken Y, Verbeken G, Degueldre J, Dellicour S, Cuypers L, T'Sas F, Van den Eede G, Verhasselt B, Weuts W, Smets C, Mertens J, Geeraerts P, Ariën KK, André E, Neirinckx P, Soentjens P, and Baele G
- Subjects
- Afghanistan epidemiology, Belgium, COVID-19 epidemiology, China epidemiology, Democratic Republic of the Congo epidemiology, Genome, Viral, Genomics, Humans, Mali epidemiology, Molecular Epidemiology, Mutation, Niger epidemiology, Phylogeny, Travel, Whole Genome Sequencing, COVID-19 virology, Military Personnel, SARS-CoV-2 classification, SARS-CoV-2 genetics
- Abstract
More than a year after the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of the 2019 coronavirus disease (COVID-19) in China, the emergence and spread of genomic variants of this virus through travel raise concerns regarding the introduction of lineages in previously unaffected regions, requiring adequate containment strategies. Concomitantly, such introductions fuel worries about a possible increase in transmissibility and disease severity, as well as a possible decrease in vaccine efficacy. Military personnel are frequently deployed on missions around the world. As part of a COVID-19 risk mitigation strategy, Belgian Armed Forces that engaged in missions and operations abroad were screened (7683 RT-qPCR tests), pre- and post-mission, for the presence of SARS-CoV-2, including the identification of viral lineages. Nine distinct viral genotypes were identified in soldiers returning from operations in Niger, the Democratic Republic of the Congo, Afghanistan, and Mali. The SARS-CoV-2 variants belonged to major clades 19B, 20A, and 20B (Nextstrain nomenclature), and included "variant of interest" B.1.525, "variant under monitoring" A.27, as well as lineages B.1.214, B.1, B.1.1.254, and A (pangolin nomenclature), some of which are internationally monitored due to the specific mutations they harbor. Through contact tracing and phylogenetic analysis, we show that isolation and testing policies implemented by the Belgian military command appear to have been successful in containing the influx and transmission of these distinct SARS-CoV-2 variants into military and civilian populations.
- Published
- 2021
- Full Text
- View/download PDF
22. A Cluster of Plasmodium ovale Infections in Belgian Military Personnel after Deployment in Kindu, Democratic Republic of Congo: A Retrospective Study.
- Author
-
Costescu Strachinaru DI, Wauters A, Van Esbroeck M, Strachinaru M, Vanbrabant P, and Soentjens P
- Abstract
Plasmodium ovale malaria is often neglected due to its less severe course compared to Plasmodium falciparum . In 2011-2012, Belgian Armed Forces identified a cluster of P. ovale cases among military personnel after deployment in the Democratic Republic of Congo (DRC). In this retrospective, monocentric, observational study, clinical and biological features of soldiers diagnosed with P. ovale after deployment in DRC were reviewed. Species diagnosis was based on polymerase chain reaction (PCR) and/or thick blood smear. Medical records of 149 soldiers screened at the Queen Astrid Military Hospital after deployment were reviewed. Eight cases (seven P. ovale infections and one P. ovale-falciparum coinfection) were identified. All had positive thick smears, and seven were confirmed by PCR. Chemoprophylaxis was mefloquine in all subjects. Median time of disease onset was 101 days after return from the endemic region. Median delay between return and diagnosis was 103 days. All P. ovale bouts were uncomplicated. None had relapses after primaquine treatment. This military cohort highlights a hotspot of P. ovale in Eastern DRC. Non-specific symptoms, the less severe presentation, the lack of sensitive parasitological tools in the field and long delays between infection and symptoms probably lead to underestimation of P. ovale cases.
- Published
- 2021
- Full Text
- View/download PDF
23. Acute Schistosomiasis With a Schistosoma mattheei × Schistosoma haematobium Hybrid Species in a Cluster of 34 Travelers Infected in South Africa.
- Author
-
Cnops L, Huyse T, Maniewski U, Soentjens P, Bottieau E, Van Esbroeck M, and Clerinx J
- Subjects
- Adult, Animals, Child, Humans, Microscopy, Schistosoma, Schistosoma haematobium, South Africa, Urinalysis, Schistosomiasis diagnosis, Schistosomiasis epidemiology, Schistosomiasis haematobia
- Abstract
Background: Diagnosis of schistosomiasis remains elusive soon after infection. We evaluated several diagnostic methods in a cluster of travelers with simultaneous freshwater exposure in South Africa., Methods: Eosinophil count, schistosome antibody tests, stool and urine microscopy, and serum Dra1 PCR assays were performed at weeks 4-5 (early symptomatic phase), 7-8 (praziquantel treatment), and 13-14 (after treatment). Sequencing was done on serum samples from 3 patients to identify the species., Results: Of the 34 travelers (16 adults and 18 children), 32 developed symptoms 2-6 weeks after exposure. A raised eosinophil count (>750/µL) was seen in 12 of 33 at weeks 4-5, and in 22 of 34 at weeks 7-8. Schistosoma antibodies were detected in 3 of 33 at weeks 4-5 and in 12 of 34 at weeks 7-8 and weeks 13-14. The Dra1 PCR result was positive in 24 of 33 travelers at weeks 4-5, in 31 of 34 at weeks 7-8, in 25 of 34 at weeks 13-14, and at least once in all. Ova were absent in all urine and stool samples obtained. Sequencing identified Schistosoma mattheei nuclear and Schistosoma haematobium mitochondrial DNA, indicative of a hybrid species., Conclusions: The Dra1 PCR confirmed the diagnosis in all exposed travelers at a much earlier stage than conventional tests. The causative species is probably an S. mattheei × S. haematobium hybrid., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
24. Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium.
- Author
-
Soentjens P, Croughs M, Burm C, Declerq S, Clerinx J, Maniewski U, Van Den Broucke S, Theunissen C, Huits R, Brosius I, Florence E, Kenyon C, Van Griensven J, Van Ierssel S, Lynen L, Balliauw K, Van Gucht S, Van Esbroeck M, Vlieghe E, Bottieau E, and Van Herrewege Y
- Subjects
- Animals, Antibodies, Viral, Antibody Formation, Belgium, Dogs, Humans, Post-Exposure Prophylaxis, Retrospective Studies, Rabies prevention & control, Rabies Vaccines, Rabies virus
- Abstract
Background : Data on rabies post-exposure prophylaxis (PEP) and the use of human rabies immunoglobulins (HRIG) in Belgium are scarce. The main objective of this study was to evaluate the timely administration of HRIG after rabies exposure. The secondary objective was to evaluate the adequate antibody response following PEP. Methods : We reviewed all medical records from July 2017 to June 2018 of patients seeking care at, or referred to, the Institute of Tropical Medicine and the University Hospital, Antwerp for the administration of human rabies immunoglobulins following potential rabies exposure abroad or in Belgium.A timely response was defined as starting HRIG with a delay of ≤48 h and rabies vaccination in the first 7 days after exposure.Adequate antibody response was defined as a titer of >5.0 IU/mL in case of bat-related exposure and >3.0 IU/mL in case of exposure to other animals. Titers were measured 10 days after the last PEP vaccine dose, using the rapid fluorescent focus inhibition test (RFFIT). Results : Of the 92 cases treated with HRIG, 75 were evaluated.The majority of injuries were acquired in Asia (n = 26,34%) and in Western Europe (n = 18, 24%), of which 17 in Belgium. The five most frequently recorded countries overseas were Indonesia (n = 13), Thailand (n = 7), Morocco (n = 4), Peru (n = 3) and Costa Rica (n = 3). Administration of immunoglobulins was related to injuries by dogs (36%), monkeys (25%) or bats (22%).A timely response was observed in 16 (21,33%) and in 55 (73,33%) of subjects receiving HRIG (≤48 h) or rabies vaccine (<7days) respectively. The mean time between exposure and the first administered dose of rabies vaccine and HRIG was 7.7 and 8.7 days, respectively. The mean delay for HRIG administration was 9.6 days and 6 days for abroad and inland risks, respectively.In 15 of 16 (94%) bat-related cases the antibody titer after full PEP was >5.0 IU/ml. In 38 of 47 (81%) cases related to other animals the RFFIT titer was >3.0 IU/ml. All low-responders received additional rabies injections. Conclusion : This study showed a substantial time delay between the animal-related risk and the administration of HRIG, in particular when the injury occurred abroad. More targeted communication about the risks of rabies and preventable measures may reduce this delay.Furthermore, the antibody response was inadequate in some cases following full PEP administration according to the Belgian recommendation.
- Published
- 2021
- Full Text
- View/download PDF
25. Diagnosis of Mycobacterium marinum Infection with Sporotrichoid Pattern.
- Author
-
Costescu Strachinaru DI, Vanbrabant P, Stinga P, Strachinaru M, and Soentjens P
- Subjects
- Anti-Bacterial Agents therapeutic use, Humans, Mycobacterium Infections, Nontuberculous diagnosis, Mycobacterium Infections, Nontuberculous drug therapy, Skin Diseases, Bacterial diagnosis, Skin Diseases, Bacterial drug therapy
- Published
- 2021
- Full Text
- View/download PDF
26. Vaccinating children in high-endemic rabies regions: what are we waiting for?
- Author
-
Soentjens P, Berens-Riha N, Van Herrewege Y, Van Damme P, Bottieau E, and Ravinetto R
- Subjects
- Child, Humans, Rabies epidemiology, Rabies prevention & control
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2021
- Full Text
- View/download PDF
27. Simplified rabies pre-exposure prophylaxis in last-minute travellers.
- Author
-
Soentjens P and Croughs M
- Subjects
- Humans, Post-Exposure Prophylaxis, Travel, Pre-Exposure Prophylaxis, Rabies prevention & control, Rabies Vaccines
- Published
- 2021
- Full Text
- View/download PDF
28. Screening the asymptomatic soldiers after a stay in sub-Saharan Africa. A retrospective observational study.
- Author
-
Vanbrabant P, Damanet B, Maussen C, Van Esbroeck M, and Soentjens P
- Subjects
- Adult, Africa South of the Sahara epidemiology, Animals, Female, Humans, Male, Retrospective Studies, Travel, Military Personnel, Strongyloides stercoralis
- Abstract
Background: Many tropical clinics offer post-travel screening for parasitic infections in asymptomatic travellers. However, literature on attack rates and incidence rates of parasitic infections is scarce., Method: All military personnel returning from a tropical region during the year 2018 were tested for the presence of antibodies against Strongyloides stercoralis, Schistosoma and Entamoeba histolytica. Test results were compared with previous results if available to distinguish recent and old infection., Results: In total, 949 soldiers were included in the study. The median age was years 31 (IQR: 26-41), 96.3% were male. The median duration of stay in the tropics was 35 days (IQR: 14-90). The destination was predominantly central Africa. Serological tests were positive for S. stercoralis in 10 patients (1.1%), Schistosoma in 3 (0.3%), and E. histolytica in 16 (1.7%). The attack rates were 0.84, 0.32 and 1.69 respectively. The incidence rates were 3.99, 1.49 and 7.97 respectively., Conclusions: The risk for parasitic infection in the asymptomatic returning soldiers is low. However, the potentially serious complications of unrecognised parasitic infection can legitimise systematic screening., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
29. Redefining Non-Inferiority in Anamnestic Antibody Responses Using the Mean Increase of Log-Transformed Antibody Titers after Revaccination: Secondary Analysis of a Randomized Controlled Rabies Vaccination Trial.
- Author
-
Overduin LA, Soentjens PHP, Goeman JJ, Berkowska MA, van Dongen JJM, and Visser LG
- Abstract
Non-inferiority in the anamnestic antibody response is conventionally determined by comparing seroconversion rates after revaccination. However, this approach is inadequate in the case of high pre-booster antibody titers. Therefore, we propose an alternative method to determine non-inferiority of booster responses. We used anonymized data from a randomized controlled trial (NCT01388985; EudraCT 2011-001612-62) in 500 adults, comparing a two-visit primary vaccination schedule (two intradermal 0.1 mL rabies vaccine doses on day 0 and 7) with a three-visit schedule (single intradermal 0.1 mL dose on day 0, 7, and 28). Participants were revaccinated intradermally (single dose) 1 to 3 years later. Rabies virus neutralizing antibody titers were measured on day 0 and 7 after revaccination. After log
3 -transformation of antibody titers, the mean increase in titers after revaccination was compared between schedules. Non-inferiority was defined as the lower bound of the two-sided 95% confidence interval not exceeding -0.369. Four hundred and ten participants fulfilled the inclusion criteria. The mean increase in log3 titer was 2.21 and 2.31 for the two-visit and three-visit schedule, respectively. The difference between these increases was -0.10 [-0.28, 0.08], meeting the non-inferiority criterion. In conclusion, comparing mean increases in log-transformed titers after revaccination appears to be a feasible and more informative method of studying non-inferiority regarding the anamnestic antibody response.- Published
- 2020
- Full Text
- View/download PDF
30. A risk scoring system to identify travellers who qualify for pre-exposure rabies vaccination.
- Author
-
Croughs M and Soentjens P
- Subjects
- Humans, Risk Factors, Travel, Vaccination, Bites and Stings, Rabies prevention & control, Rabies Vaccines
- Published
- 2020
- Full Text
- View/download PDF
31. Stock shortages of the rabies vaccine in Belgium: implications for pretravel advice.
- Author
-
Soentjens P and Croughs M
- Subjects
- Belgium, Humans, Rabies prevention & control, Rabies Vaccines
- Published
- 2020
- Full Text
- View/download PDF
32. Factors influencing the immune response after a single-dose 3-visit pre-exposure rabies intradermal vaccination schedule: A retrospective multivariate analysis.
- Author
-
Damanet B, Costescu Strachinaru DI, Van Nieuwenhove M, and Soentjens P
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Belgium, Humans, Immunity, Immunization Schedule, Injections, Intradermal, Multivariate Analysis, Retrospective Studies, Vaccination, Rabies, Rabies Vaccines, Rabies virus immunology
- Abstract
Background: The World Health Organization (WHO) recommends intradermal (ID) rabies vaccination as a safe and immunogenic alternative to intramuscular administration. The aim of this study is to determine which factors influence the levels of rabies virus neutralizing antibodies (RVNA) after a 3-visit ID rabies vaccination., Methods: This is a retrospective secondary data analysis study based on electronic health record vaccination data of Belgian military subjects who received ID rabies Pre-exposure prophylaxis (PrEP) with a single-dose 3-visit regimen during the period 2014-2017. Logistic regression was performed to identify predictive factors of RVNA level ≥3.0 IU/mL and >10 IU/mL., Results: The second analysis performed on the 2025 subjects (100% seroconverted with a RVNA ≥ 0.5 IU/mL) shows a significantly better immune response in subjects younger than 30 years compared to all other age-groups, a gender-difference to predict RVNA ≥ 3.0 IU/mL (OR 2.30 [1.26-4.22] comparing "female" to "male") and the influence of the vaccination schedule (OR 2.28 [1.15-4.53] comparing "late - very variable" to "correct" schedule) to predict > 10 IU/ml. Multivariate analysis also demonstrates that a postponed serology control significantly influences the Rapid Fluorescent Focus Inhibition Test (RFFIT)., Conclusion: Gender and age significantly influence the response to ID rabies vaccine. Timing of RVNA determination is important to correctly assess the response to vaccination. A single-dose 3-visit ID rabies PrEP schedule is a dose-sparing effective alternative to the double-dose 2-visit ID schedule. When the minimum time interval between doses is respected, RVNA determination is not necessary., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
33. Study of a SARS-CoV-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger.
- Author
-
Pirnay JP, Selhorst P, Cochez C, Petrillo M, Claes V, Van der Beken Y, Verbeken G, Degueldre J, T'Sas F, Van den Eede G, Weuts W, Smets C, Mertens J, Geeraerts P, Ariën KK, Neirinckx P, and Soentjens P
- Subjects
- Adult, Belgium epidemiology, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques, Coronavirus Infections diagnosis, Disease Outbreaks, Humans, Male, Molecular Epidemiology, Niger epidemiology, Pandemics, Pneumonia, Viral diagnosis, Real-Time Polymerase Chain Reaction methods, SARS-CoV-2, Serologic Tests, Viral Load, Young Adult, Betacoronavirus isolation & purification, Coronavirus Infections epidemiology, Military Personnel statistics & numerical data, Pneumonia, Viral epidemiology
- Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compromises the ability of military forces to fulfill missions. At the beginning of May 2020, 22 out of 70 Belgian soldiers deployed to a military education and training center in Maradi, Niger, developed mild COVID-19 compatible symptoms. Immediately upon their return to Belgium, and two weeks later, all seventy soldiers were tested for SARS-CoV-2 RNA (RT-qPCR) and antibodies (two immunoassays). Nine soldiers had at least one positive COVID-19 diagnostic test result. Five of them exhibited COVID-19 symptoms (mainly anosmia, ageusia, and fever), while four were asymptomatic. In four soldiers, SARS-CoV-2 viral load was detected and the genomes were sequenced. Conventional and genomic epidemiological data suggest that these genomes have an African most recent common ancestor and that the Belgian military service men were infected through contact with locals. The medical military command implemented testing of all Belgian soldiers for SARS-CoV-2 viral load and antibodies, two to three days before their departure on a mission abroad or on the high seas, and for specific missions immediately upon their return in Belgium. Some military operational settings (e.g., training camps in austere environments and ships) were also equipped with mobile infectious disease (COVID-19) testing capacity.
- Published
- 2020
- Full Text
- View/download PDF
34. 'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
- Author
-
Soentjens P, Van Damme P, and Bottieau E
- Subjects
- Child, Humans, Injections, Intradermal, Post-Exposure Prophylaxis, Rabies epidemiology, Rabies prevention & control
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2020
- Full Text
- View/download PDF
35. Improved information tools and measures are needed for the last-minute traveller.
- Author
-
Soentjens P
- Subjects
- Humans, Health Knowledge, Attitudes, Practice
- Published
- 2020
- Full Text
- View/download PDF
36. Factors influencing the immune response after a double-dose 2-visit pre-exposure rabies intradermal vaccination schedule: A retrospective study.
- Author
-
Damanet B, Costescu Strachinaru DI, and Soentjens P
- Subjects
- Adult, Belgium, Female, Humans, Injections, Intradermal, Male, Middle Aged, Military Personnel, Rabies immunology, Retrospective Studies, Young Adult, Immunization Schedule, Pre-Exposure Prophylaxis methods, Rabies prevention & control, Rabies Vaccines immunology
- Abstract
Background: Double-dose 2-visit intradermal rabies schedules (2
2 ID) have recently been accepted by the World Health Organization (WHO) as Pre-Exposure Prophylaxis (PrEP). The aim of this study is to determine which factors influence the levels of rabies virus neutralizing antibodies (RVNA) after a 22 ID rabies vaccination schedule., Methods: This is a retrospective study based on electronic health record vaccination data of subjects from the Belgian Armed Forces who received the 22 ID rabies PrEP. An antibody titer ≥0.5 IU/mL, measured by rapid fluorescent focus inhibition test, is defined by the WHO as an adequate immune response after PrEP. Logistic regression was performed in order to identify predictive factors of RVNA level ≥3.0 IU/ml and >10 IU/ml., Results: 301 subjects were included. 297 (98,6%) seroconverted with a RVNA ≥ 0.5 IU/ml. Multivariate analysis shows a significant better immune response in the subjects where the second dose was administered later on than on day 7 (RVNA >10 IU/ml (OR: 3.01 [1.36-6.67])). Postponing the timing of the serology control also influenced significantly the rapid fluorescent focus inhibition test (RVNA ≥ 3.0 IU/ml (OR: 0.12 [0.06-0.24]) and RVNA > 10 IU/ml (OR: 0.14 [0.06-0.29]))., Conclusion: A 22 ID rabies PrEP vaccination schedule is highly effective and provides an adequate immune response in most subjects in a real live setting. Timing of the second vaccine dose significantly influences the response to ID rabies vaccine. Timing of RVNA determination is important in order to correctly assess the response to vaccination., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2020 Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
37. Streptococcal toxic shock syndrome in a returning traveller.
- Author
-
Note S, Soentjens P, Van Laer M, Meert P, and Vanbrabant P
- Subjects
- Anti-Bacterial Agents classification, Communicable Diseases, Imported diagnosis, Communicable Diseases, Imported etiology, Diagnosis, Differential, Female, Humans, Middle Aged, Patient Care Management methods, Purpura Fulminans diagnosis, Purpura Fulminans therapy, Surgical Procedures, Operative methods, Travel-Related Illness, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Fasciitis, Necrotizing complications, Fasciitis, Necrotizing diagnosis, Fasciitis, Necrotizing therapy, Fluid Therapy methods, Shock, Septic diagnosis, Shock, Septic etiology, Shock, Septic therapy, Streptococcal Infections diagnosis, Streptococcal Infections physiopathology, Streptococcal Infections therapy, Streptococcus pyogenes isolation & purification
- Abstract
Background: A patient presenting with fever and purpura after a stay in the tropics tempts a physician to make a differential diagnosis mainly focusing on imported diseases. Although the importance of considering a tropical disease is obvious, the fact that cosmopolitan infections account for one third of the cases in a febrile returning traveler must not be overseen. Toxic Shock Syndrome is amongst the most notorious diseases due to the high mortality when inappropriately managed and the association with necrotizing fasciitis. Methods : We present a 60-year old female with fever, shock syndrome and progressive appearance of painful purpura on the lower legs after a 2-week holiday in Zanzibar. Results : The patient was diagnosed with Streptococcal Toxic Shock Syndrome. Treatment focusing on aggressive fluid resuscitation, prompt administration of antibiotics (ceftriaxon, doxycycline and one dose of amikacin) and adjunctive treatment by clindamycin and immunoglobulin was initiated. She was also immediately taken into surgery for a bilateral fasciotomy and surgical exploration of the lower legs. Histology appeared compatible with purpura fulminans, thereby excluding necrotizing fasciitis. No source of infection could be identified. Conclusion : Toxic Shock Syndrome remains a challenging diagnosis and even more in a returning traveler with an extensive differential diagnosis containing both tropical and cosmopolitan diseases. Cornerstones for the treatment of Streptococcal Toxic Shock Syndrome are abrupt administration of antimicrobial therapy comprising beta-lactam antibiotics and clindamycin and surgical exploration to apply source control when indicated.
- Published
- 2019
- Full Text
- View/download PDF
38. Low adherence with national travel medicine recommendations in Belgian expatriate children: A retrospective analysis.
- Author
-
Decuyper II, Van Damme P, Soentjens P, and Wojciechowski M
- Abstract
Background: Expatriates (expats) from European countries regularly migrate to low-income countries where infectious diseases are more prevalent. Little evidence exists however on pediatric expatriates' compliance with preventive measures related to infectious diseases. This study aims to evaluate compliance in Belgian expat-children., Methods: Data of 135 Belgian expat-children, visiting the Institute of Tropical Medicine (Antwerp, Belgium), were collected from clinical notes, laboratory results and from a web-based immunization-register. Information on routine vaccinations, yellow fever, hepatitis A, rabies, typhoid fever, meningococcal ACW
135 Y, Japanese encephalitis, BCG vaccine and anti-malaria chemoprophylaxis was collected., Results: Overall, 87% of expat-children were up-to-date with their routine vaccinations. Although all children were eligible for hepatitis A, typhoid and rabies vaccination, only 8-21% were fully vaccinated. Only 29 and 61% of eligible children were vaccinated against meningococcal (ACW135 Y) or yellow fever respectively. Finally, only 10% of children who lived in malaria-endemic-areas, reported chemoprophylaxis-use., Conclusion: Although routine vaccination coverage in expat-children seems adequate, additional preventive measures are often needed. Whether this is due to lack of high-quality health care-access, fear of side-effects or insufficient knowledge about the risks/available preventive measures, remains elusive. Nevertheless, expats seem to constitute a separate risk-group for infectious diseases and destination-related health issues., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
39. Timing of Intradermal Rabies Pre-exposure Prophylaxis Injections: Immunological Effect on Vaccination Response.
- Author
-
Van Nieuwenhove MDM, Damanet B, and Soentjens P
- Subjects
- Adult, Antibodies analysis, Antibodies blood, Belgium, Female, Humans, Injections, Intradermal methods, Male, Middle Aged, Pre-Exposure Prophylaxis methods, Pre-Exposure Prophylaxis statistics & numerical data, Rabies drug therapy, Rabies Vaccines classification, Rabies Vaccines therapeutic use, Retrospective Studies, Seroconversion drug effects, Pre-Exposure Prophylaxis standards, Rabies prevention & control, Rabies Vaccines standards, Time Factors
- Abstract
Introduction: Rabies remains a global threat, with annually over 59,000 deaths. Intradermal (ID) pre-exposure prophylaxis (PrEP) is very efficient and reduces the need for rabies immunoglobulins. Not much is known about factors that influence the immune response to ID administered rabies vaccine. The aim of this study is to determine if variations in timing of vaccine administration and serology determination, age and gender have an influence on the levels of rabies virus neutralizing antibody (RVNA) after ID rabies vaccination., Materials and Methods: This is a retrospective study based on electronic health record vaccination data of Belgian military personnel who received ID rabies PrEP with a three injections regimen during the period 2014-2017. Serology was determined by using the RFFIT method. Fischer's exacts tests were used to evaluate the effect of each independent variable on RVNA levels., Results: In this study, 2,112 subjects were included. All but one seroconverted with a RVNA level ≥0.5 IU/mL. About 48% of subjects developed an antibody titer of >10 IU/mL, 36% had antibody levels 3-10 IU/mL and 16% had an antibody level 0.5-2.99 IU/mL. Statistically significant (p = 0.0018) higher RVNA levels are observed in the groups that received vaccination doses later as planned. Timing of serology determination also influenced RVNA levels significantly (p = 0.000). Antibody levels were significantly higher in females than in males (p = 0.000). Age did influence RVNA levels significantly (p = 0.022)., Conclusions: Timing of vaccine dose administration, timing of serology testing, sex and age do significantly influence the humoral B-cell response to ID administered rabies vaccine., (© Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
40. Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol.
- Author
-
Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, De Munter P, Debaveye Y, Nijs S, Vanderschot P, Wagemans J, Pirnay JP, Lavigne R, and Metsemakers WJ
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Bacteria classification, Bacteria drug effects, Bacteria isolation & purification, Bacteria virology, Bacteriolysis, Clinical Protocols standards, Combined Modality Therapy, Drug Resistance, Multiple, Bacterial, Humans, Microbial Sensitivity Tests, Musculoskeletal Diseases microbiology, Osteomyelitis microbiology, Osteomyelitis therapy, Perioperative Period, Treatment Outcome, Bacteriophages, Musculoskeletal Diseases therapy, Patient Care Team standards, Phage Therapy methods, Phage Therapy standards
- Abstract
Bacteriophage therapy has recently attracted increased interest, particularly in difficult-to-treat infections. Although it is not a novel concept, standardized treatment guidelines are currently lacking. We present the first steps towards the establishment of a "multidisciplinary phage task force" (MPTF) and a standardized treatment pathway, based on our experience of four patients with severe musculoskeletal infections. After review of their medical history and current clinical status, a multidisciplinary team found four patients with musculoskeletal infections eligible for bacteriophage therapy within the scope of Article 37 of the Declaration of Helsinki. Treatment protocols were set up in collaboration with phage scientists and specialists. Based on the isolated pathogens, phage cocktails were selected and applied intraoperatively. A draining system allowed postoperative administration for a maximum of 10 days, 3 times per day. All patients received concomitant antibiotics and their clinical status was followed daily during phage therapy. No severe side-effects related to the phage application protocol were noted. After a single course of phage therapy with concomitant antibiotics, no recurrence of infection with the causative strains occurred, with follow-up periods ranging from 8 to 16 months. This study presents the successful outcome of bacteriophage therapy using a standardized treatment pathway for patients with severe musculoskeletal infection. A multidisciplinary team approach in the form of an MPTF is paramount in this process., Competing Interests: The authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
41. Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination.
- Author
-
Soentjens P, De Koninck K, Tsoumanis A, Herssens N, Van Den Bossche D, Terryn S, Van Gucht S, Van Damme P, Van Herrewege Y, and Bottieau E
- Subjects
- Adolescent, Adult, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Female, Humans, Immunization, Secondary, Injections, Intradermal, Injections, Intramuscular, Male, Rabies Vaccines administration & dosage, Vaccination statistics & numerical data, Young Adult, Immunization Schedule, Post-Exposure Prophylaxis, Rabies prevention & control, Rabies Vaccines immunology
- Abstract
Background: Effective and safe single-visit rabies vaccination for pre- and postexposure prophylaxis (PrEP and PEP) could substantially simplify rabies prevention and therefore increase compliance., Methods: In a comparative trial, 303 healthy adults received a primary vaccination that consisted of 2 intradermal (ID) doses of 0.1 mL of the purified chicken embryo cell vaccine (PCEV) during a single visit. One year later, participants were randomly assigned to receive either 4 or 2 ID PEP booster doses of 0.1 mL PCEV during a single visit. The primary endpoint for immunogenicity was the percentage of participants with an adequate antibody level (>0.5 IU/mL) 7 days after the booster doses. The safety endpoint was the proportion of participants who developed adverse events (AEs) following primary and/or booster vaccination., Results: All participants, except 1 (99.3%) in each study group, had a rabies antibody titer >0.5 IU/mL on day 7 following the booster schedules. Participants exposed to the 4-dose PEP schedule had a geometric mean titer of 20 IU/mL vs 14 IU/mL for the 2-dose PEP schedule (P = .0228). Local reactions at the injection site following PrEP and PEP were mild and transient and only seen in 14.9% and 49.6%-53% of the participants, respectively. No serious AEs were reported., Conclusions: In healthy adults, a 2-dose (2 × 0.1 mL) single-visit ID PEP schedule was as immunologically adequate and safe as a 4-dose (4 × 0.1 mL) single-visit PEP schedule 7 to 28 months following a 2-dose (2 × 0.1 mL) single-visit ID PREP., Clinical Trials Registration: EudraCT 2014-00183612., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
42. Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified.
- Author
-
Djebara S, Maussen C, De Vos D, Merabishvili M, Damanet B, Pang KW, De Leenheer P, Strachinaru I, Soentjens P, and Pirnay JP
- Subjects
- Adolescent, Adult, Aged, Belgium, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Young Adult, Anti-Bacterial Agents therapeutic use, Bacterial Infections therapy, Health Services Needs and Demand, Hospitals, Military, Patient Preference, Phage Therapy
- Abstract
There is a growing interest in phage therapy as a complementary tool against antimicrobial resistant infections. Since 2007, phages have been used sporadically to treat bacterial infections in well-defined cases in the Queen Astrid military hospital (QAMH) in Brussels, Belgium. In the last two years, external requests for phage therapy have increased significantly. From April 2013 to April 2018, 260 phage therapy requests were addressed to the QAMH. Of these 260 requests, only 15 patients received phage therapy. In this paper, we analyze the phage therapy requests and outcomes in order to improve upon the overall capacity for phage therapy at the QAMH.
- Published
- 2019
- Full Text
- View/download PDF
43. Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days.
- Author
-
Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, van Loen H, Brochier B, Van Gucht S, Van Damme P, Van Herrewege Y, and Bottieau E
- Subjects
- Adolescent, Adult, Antibodies, Viral blood, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, Healthy Volunteers, Humans, Injections, Intradermal, Male, Middle Aged, Rabies Vaccines adverse effects, Treatment Outcome, Young Adult, Immunization Schedule, Rabies prevention & control, Rabies Vaccines administration & dosage, Rabies Vaccines immunology
- Abstract
Background: The existing 4-week preexposure rabies vaccination schedule is costly and often not practicable. Shorter effective schedules would result in wider acceptance., Methods: We conducted a noninferiority trial in 500 healthy adults comparing the safety and immunogenicity of a 2-visit (days 0 and 7) intradermal (ID) primary vaccination (2 doses of 0.1 mL ID of the human diploid cell culture rabies vaccine [HDCV] at days 0 and 7) vs a standard 3-visit schedule (single dose of 0.1 mL ID at days 0, 7, and 28). One year to 3 years after primary vaccination, a single booster dose of 0.1 mL ID of HDCV was given to evaluate the anamnestic rabies antibody response. The primary endpoint for immunogenicity was the percentage of subjects with an adequate antibody level >0.5 IU/mL 7 days after the booster injection. The safety endpoint was the proportion of participants developing adverse reactions following the primary vaccination and/or booster dose., Results: All subjects in both study groups possessed a rabies antibody titer >0.5 IU/mL on day 7 following the booster dose. Following the booster dose, subjects exposed to the double-dose 2-visit ID schedule had a geometric mean titer of 37 IU/mL, compared with 25 IU/mL for the single-dose 3-visit schedule (P < .001). Local reactions at the injection site following primary vaccination were mild and transient., Conclusions: In healthy adults, ID administration of a double dose of 0.1 mL of HDCV over 2 visits (days 0 and 7) was safe and not inferior to the single-dose 3-visit schedule., Clinical Trials Registration: NCT01388985, EudraCT 2011-001612-62.
- Published
- 2019
- Full Text
- View/download PDF
44. Selection of Potential Therapeutic Bacteriophages that Lyse a CTX-M-15 Extended Spectrum β-Lactamase Producing Salmonella enterica Serovar Typhi Strain from the Democratic Republic of the Congo.
- Author
-
Kakabadze E, Makalatia K, Grdzelishvili N, Bakuradze N, Goderdzishvili M, Kusradze I, Phoba MF, Lunguya O, Lood C, Lavigne R, Jacobs J, Deborggraeve S, De Block T, Van Puyvelde S, Lee D, Coffey A, Sedrakyan A, Soentjens P, De Vos D, Pirnay JP, and Chanishvili N
- Subjects
- Bacteriolysis, Bacteriophages classification, Bacteriophages ultrastructure, Democratic Republic of the Congo, Genome, Viral, Humans, Phage Therapy, Phylogeny, Salmonella typhi isolation & purification, Typhoid Fever therapy, Bacteriophages physiology, Salmonella typhi genetics, Salmonella typhi virology, Typhoid Fever microbiology, beta-Lactamases genetics
- Abstract
Recently, a Salmonella Typhi isolate producing CTX-M-15 extended spectrum β-lactamase (ESBL) and with decreased ciprofloxacin susceptibility was isolated in the Democratic Republic of the Congo. We have selected bacteriophages that show strong lytic activity against this isolate and have potential for phage-based treatment of S . Typhi, and Salmonella in general., Competing Interests: The authors declare no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
45. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report.
- Author
-
Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, and Pirnay JP
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Colistin therapeutic use, Humans, Male, Middle Aged, Pseudomonas Infections complications, Pseudomonas aeruginosa pathogenicity, Sepsis complications, Sepsis drug therapy, Acute Kidney Injury etiology, Bacteriophages, Colistin pharmacology, Pseudomonas Infections drug therapy
- Published
- 2017
- Full Text
- View/download PDF
46. Clinical Utility of the Nonstructural 1 Antigen Rapid Diagnostic Test in the Management of Dengue in Returning Travelers With Fever.
- Author
-
Huits R, Soentjens P, Maniewski-Kelner U, Theunissen C, Van Den Broucke S, Florence E, Clerinx J, Vlieghe E, Jacobs J, Cnops L, Van Den Bossche D, Van Esbroeck M, and Bottieau E
- Abstract
Background: Rapid diagnostic test (RDT) detecting the nonstructural 1 (NS1) antigen is increasingly used for dengue diagnosis in endemic and nonendemic settings, but its clinical utility has not been studied in travel clinic practice., Methods: From August 2012 to July 2016, travelers returning from the tropics with fever were evaluated in the Institute of Tropical Medicine (Antwerp, Belgium) with the routine use of NS1 antigen RDT that provided results within 1 hour. We determined the diagnostic performance, assessed the management of patients with a positive RDT result, and compared it with that of historical cases of dengue diagnosed from 2000 to 2006, when only antibody detection assays were available., Results: Of 335 travelers evaluated for fever, 54 (16%) were diagnosed with dengue, including 1 severe case. Nonstructural 1 antigen RDT was performed in 308 patients. It was truly positive in 43 of 52 tested dengue cases and falsely positive in only 1 of the 256 nondengue cases; therefore, sensitivity was 82.7% (95% confidence interval [CI], 74.4%-93.0%) and specificity was 99.6% (95% CI, 98.8%-100%). Only 3 (7%) of the 43 febrile travelers "immediately" diagnosed by RDT were admitted, and only 2 (5%) were given empirical antibacterial treatment, without adverse outcome. Admission and antibiotic prescription rates were significantly higher in the historical cases (n = 43) diagnosed by antibody detection (33%, P = .006 and 26%, P = .014, respectively), although the frequency of severe dengue was similar., Conclusions: In our practice, the diagnostic performance of NS1 antigen RDT substantially contributed in withholding unnecessary hospitalization and antibiotherapy in dengue patients., (© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2017
- Full Text
- View/download PDF
47. Diagnosis and Clinical Management of Schistosoma haematobium-Schistosoma bovis Hybrid Infection in a Cluster of Travelers Returning From Mali.
- Author
-
Soentjens P, Cnops L, Huyse T, Yansouni C, De Vos D, Bottieau E, Clerinx J, and Van Esbroeck M
- Subjects
- Animals, DNA, Helminth, Feces parasitology, Female, Genotyping Techniques, Mali, Ovum, Schistosoma genetics, Schistosomiasis parasitology, Schistosomiasis therapy, Schistosomiasis haematobia diagnosis, Schistosomiasis haematobia parasitology, Schistosomiasis haematobia therapy, Hybridization, Genetic, Schistosoma haematobium genetics, Schistosomiasis diagnosis, Travel
- Abstract
Ten Belgian travelers returned from Mali with a Schistosoma haematobium-Schistosoma bovis hybrid infection, confirmed by DNA sequencing from eggs. Clinical symptoms and laboratory findings resembled those of classic acute schistosomiasis, but the detected eggs were morphologically unusual., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
48. Perianal lesions after return from Togo: An isolated cutaneous manifestation of schistosomiasis.
- Author
-
Note S, Vanbrabant P, and Soentjens P
- Subjects
- Adult, Anal Canal, Animals, Belgium epidemiology, Diagnosis, Differential, Humans, Male, Schistosoma isolation & purification, Schistosomiasis ethnology, Schistosomiasis parasitology, Skin Diseases, Parasitic ethnology, Skin Diseases, Parasitic parasitology, Togo ethnology, Schistosomiasis diagnosis, Skin Diseases, Parasitic diagnosis, Travel
- Abstract
Isolated perianal lesions in a returned traveller from Togo were observed. Eosinophilia was the lead to schistosomiasis, although no systemic symptoms were reported. This case report of cutaneous schistosomiasis demonstrates the importance of a travel history, especially geographic and exposure features, and treats the differential diagnosis of eosinophilia in a returned traveller with skin lesions.
- Published
- 2016
- Full Text
- View/download PDF
49. Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center.
- Author
-
De Vos D, Pirnay JP, Bilocq F, Jennes S, Verbeken G, Rose T, Keersebilck E, Bosmans P, Pieters T, Hing M, Heuninckx W, De Pauw F, Soentjens P, Merabishvili M, Deschaght P, Vaneechoutte M, Bogaerts P, Glupczynski Y, Pot B, van der Reijden TJ, and Dijkshoorn L
- Subjects
- Acinetobacter Infections microbiology, Acinetobacter baumannii genetics, Acinetobacter calcoaceticus genetics, Adolescent, Adult, Africa, Northern epidemiology, Aged, Aged, 80 and over, Bacterial Typing Techniques, Belgium epidemiology, Child, Child, Preschool, Drug Resistance, Bacterial, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Multilocus Sequence Typing, Multiplex Polymerase Chain Reaction, RNA, Bacterial analysis, RNA, Ribosomal, 16S analysis, Treatment Outcome, Young Adult, Acinetobacter Infections drug therapy, Acinetobacter Infections epidemiology, Acinetobacter baumannii isolation & purification, Acinetobacter calcoaceticus isolation & purification, Burns microbiology, Colistin therapeutic use
- Abstract
Multidrug resistant Acinetobacter baumannii and its closely related species A. pittii and A. nosocomialis, all members of the Acinetobacter calcoaceticus-baumannii (Acb) complex, are a major cause of hospital acquired infection. In the burn wound center of the Queen Astrid military hospital in Brussels, 48 patients were colonized or infected with Acb complex over a 52-month period. We report the molecular epidemiology of these organisms, their clinical impact and infection control measures taken. A representative set of 157 Acb complex isolates was analyzed using repetitive sequence-based PCR (rep-PCR) (DiversiLab) and a multiplex PCR targeting OXA-51-like and OXA-23-like genes. We identified 31 rep-PCR genotypes (strains). Representatives of each rep-type were identified to species by rpoB sequence analysis: 13 types to A. baumannii, 10 to A. pittii, and 3 to A. nosocomialis. It was assumed that isolates that belonged to the same rep-type also belonged to the same species. Thus, 83.4% of all isolates were identified to A. baumannii, 9.6% to A. pittii and 4.5% to A. nosocomialis. We observed 12 extensively drug resistant Acb strains (10 A. baumannii and 2 A. nosocomialis), all carbapenem-non-susceptible/colistin-susceptible and imported into the burn wound center through patients injured in North Africa. The two most prevalent rep-types 12 and 13 harbored an OXA-23-like gene. Multilocus sequence typing allocated them to clonal complex 1 corresponding to EU (international) clone I. Both strains caused consecutive outbreaks, interspersed with periods of apparent eradication. Patients infected with carbapenem resistant A. baumannii were successfully treated with colistin/rifampicin. Extensive infection control measures were required to eradicate the organisms. Acinetobacter infection and colonization was not associated with increased attributable mortality.
- Published
- 2016
- Full Text
- View/download PDF
50. Analysis of delayed TBE-vaccine booster after primary vaccination.
- Author
-
Aerssens A, Cochez C, Niedrig M, Heyman P, Kühlmann-Rabens I, and Soentjens P
- Subjects
- Adult, Belgium, Enzyme-Linked Immunosorbent Assay, Female, Hospitals, Military, Humans, Immunization Schedule, Male, Middle Aged, Military Medicine, Neutralization Tests, Travel Medicine, Encephalitis Viruses, Tick-Borne immunology, Encephalitis, Tick-Borne prevention & control, Immunization, Secondary, Outcome Assessment, Health Care, Viral Vaccines immunology
- Abstract
An open, uncontrolled single centre study was conducted in the Travel Clinic at the Military Hospital, Brussels. Eighty-eight subjects were recruited who had a primary series of tick-borne encephalitis (TBE) vaccine more than 5 years ago and who never received a booster dose afterwards. Response rate after booster vaccination was very high: 84 out of 88 subjects (95.5%) had neutralizing antibodies on plaque reduction neutralization test and all (100%) had IgG antibodies on ELISA, on Day 21-28 after booster vaccination. This study adds valuable information to the common situation of delayed booster interval. The results of our study indicate that in young healthy travellers (<50 years), one booster vaccination after a primary series of TBE vaccine in the past is sufficient to obtain protective antibodies, even if primary vaccination is much longer than the recommended booster interval of 5 years., (© International Society of Travel Medicine, 2016. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.